The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

Endocrine Journal

Terumi Higuchi¹  Midori Ito²  Masanori Abe²  Fumito Kikuchi³  Masaaki Tsuchida⁴  Masayoshi Soma²  Noriaki Maruyama²  Hirokazu Sasaki²  Kazuyoshi Okada² 

[1] Keiai Hospital, Department of Nephrology, Tokyo, Japan;Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan;Meirikai Chuo General Hospital, Department of Nephrology, Tokyo, Japan;Tobu Nerima Clinic, Tokyo, Japan

关键词: Dipeptidyl peptidase-4 (DPP-4) inhibitor;    Glycemic control;    Hemodialysis;    Type-2 diabetes;    Vildagliptin;   

DOI  :  10.1507/endocrj.EJ11-0025

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(28)Cited-By(40)The potent and selective dipeptidyl peptidase-4 inhibitor vildagliptin improves glycemic control in patients with type 2 diabetes through incretin hormone-mediated increases in both α- and β-cell responsiveness to glucose.We conducted a prospective, open-label, parallel group, controlled study of 51 patients with type 2 diabetic patients undergoing hemodialysis (HD) during the 24-week study period.Patients were assigned to two groups: the vildagliptin group (n = 30) and the control group (n = 21).Vildagliptin was administered at 50 mg/day for the first 8 weeks.Then doses were titrated by dose-doubling to a maximum of 100 mg/day if hemoglobin A1c (HbA1c) or glycated albumin (GA) target levels had not been reached.No vildagliptin was administered to the controls.The average final dose of vildagliptin was 80 ± 5 mg daily.After 24 weeks, vildagliptin had decreased average HbA1c levels from 6.7 % baseline to 6.1 %, average GA levels from 24.5 % baseline to 20.5 % and average postprandial plasma glucose levels from 186 mg/dL baseline to 140 mg/dL (all p < 0.0001).In the control group, we observed no such changes.Vildagliptin efficacy did not differ according to age or body mass index, but the GA reduction was significantly greater in the anti-diabetic agents-naïve group.Furthermore, in patients with higher baseline GA levels, a higher vildagliptin dosage was required to produce a noticeable effect.No serious adverse effects such as hypoglycemia or liver impairment were observed in any patient.Vildagliptin was effective as a treatment for diabetic patients undergoing HD.

【 授权许可】

Unknown